Tom 6, Nr 2 (2021)
Artykuł redakcyjny na zaproszenie
Opublikowany online: 2021-04-09

dostęp otwarty

Wyświetlenia strony 159
Wyświetlenia/pobrania artykułu 114
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Well-differentiated neuroendocrine neoplasms (NENs) of the digestive system – a diagnostic and therapeutic problem

Daria Handkiewicz-Junak1, Agnieszka Czarniecka2
Biuletyn Polskiego Towarzystwa Onkologicznego Nowotwory 2021;6(2):136-137.

Streszczenie

Brak

Artykuł dostępny w formacie PDF

Pokaż PDF (angielski) Pobierz plik PDF

Referencje

  1. Baldys-Waligorska A, Nowak W. Neuroendocrine neoplasms of the digestive system-current classification and terminology. Nowotwory Journal of Oncology. 2021; 71(1): 26–37.
  2. Manguso N, Gangi A, Nissen N, et al. Long-Term Outcomes after Elective Emergency Surgery for Small Bowel Neuroendocrine Tumors. Am Surg. 2018; 84(10): 1570–1574.
  3. Sundin A, Arnold R, Baudin E, et al. Antibes Consensus Conference participants. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine & Hybrid Imaging. Neuroendocrinology. 2017; 105(3): 212–244.
  4. Knigge U, Capdevila J, Bartsch DK, et al. Antibes Consensus Conference Participants, Antibes Consensus Conference participants. ENETS Consensus Recommendations for the Standards of Care in Neuroendocrine Neoplasms: Follow-Up and Documentation. Neuroendocrinology. 2017; 105(3): 310–319.
  5. Caplin ME, Pavel M, Ćwikła JB, et al. CLARINET Investigators. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014; 371(3): 224–233.
  6. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008; 26(13): 2124–2130.
  7. Eriksson J, Garmo H, Hellman P, et al. The Influence of Preoperative Symptoms on the Death of Patients with Small Intestinal Neuroendocrine Tumors. Ann Surg Oncol. 2017; 24(5): 1214–1220.
  8. Yao JC, Fazio N, Singh S, et al. RAD001 in Advanced Neuroendocrine Tumours, Fourth Trial (RADIANT-4) Study Group. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016; 387(10022): 968–977.
  9. Chan DL, Segelov E, Singh S. Everolimus in the management of metastatic neuroendocrine tumours. Therap Adv Gastroenterol. 2017; 10(1): 132–141.
  10. Strosberg J, El-Haddad G, Wolin E, et al. NETTER-1 Trial Investigators. Phase 3 Trial of Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017; 376(2): 125–135.



Biuletyn Polskiego Towarzystwa Onkologicznego Nowotwory